Myocardial Ischemia - Pipeline Review, H2 2020

August 2020 | 90 pages | ID: M3A31D1D185EN
Global Markets Direct

Abstracts

Myocardial Ischemia - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H2 2020, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia - Overview
Myocardial Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Ischemia - Companies Involved in Therapeutics Development
Angionetics Inc
AstraZeneca Plc
Cadrock Pty Ltd
Caladrius Biosciences Inc
Cellmid Ltd
Chrysalis BioTherapeutics Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Everon Biosciences Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Lixte Biotechnology Holdings Inc
NervGen Pharma Corp
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc
Myocardial Ischemia - Drug Profiles
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-8601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocardial Ischemia - Dormant Projects
Myocardial Ischemia - Discontinued Products
Myocardial Ischemia - Product Development Milestones
Featured News & Press Releases
Feb 20, 2019: Phase 1 data published in Nature Communications show potential of mRNA encoding VEGF-A as a regenerative therapeutic
Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease
Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Myocardial Ischemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Myocardial Ischemia - Pipeline by Angionetics Inc, H2 2020
Myocardial Ischemia - Pipeline by AstraZeneca Plc, H2 2020
Myocardial Ischemia - Pipeline by Cadrock Pty Ltd, H2 2020
Myocardial Ischemia - Pipeline by Caladrius Biosciences Inc, H2 2020
Myocardial Ischemia - Pipeline by Cellmid Ltd, H2 2020
Myocardial Ischemia - Dormant Projects, H2 2020
Myocardial Ischemia - Dormant Projects, H2 2020 (Contd..1), H2 2020
Myocardial Ischemia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myocardial Ischemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Angionetics Inc
AstraZeneca Plc
Cadrock Pty Ltd
Caladrius Biosciences Inc
Cellmid Ltd
Chrysalis BioTherapeutics Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Everon Biosciences Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Lixte Biotechnology Holdings Inc
NervGen Pharma Corp
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc